Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery
It has been reported that radiation therapy followed by PCV chemotherapy (procarbazine, lomustine and vincristine) could improve progression-free survival (PFS) and overall survival (OS) in patients with high-risk WHO grade 2 gliomas after surgery. However, procarbazine is not available in China. In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide to treat these patients, though large-scale prospective studies are lacking. This trial aims to confirm whether RT combined with temozolomide can improve PFS and OS in patients with high-risk low-grade gliomas.
• Newly diagnosed supratentorial WHO grade II gliomas;
• Aged 18 to 39 years without total resection, or aged 40 to 70 years with any extent of resection or biopsy;
• Karnofsky performance score (KPS) ≥ 60;
• No more than moderate neurologic symptoms and signs;
• The interval between surgery and randomization is less than 12 weeks;
• Have signed the consent form. -